Kovack Advisors Inc. Has $6.43 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kovack Advisors Inc. boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 20.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 57,672 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,783 shares during the quarter. Jazz Pharmaceuticals comprises 0.7% of Kovack Advisors Inc.’s investment portfolio, making the stock its 28th biggest position. Kovack Advisors Inc. owned 0.09% of Jazz Pharmaceuticals worth $6,425,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Private Advisor Group LLC lifted its stake in Jazz Pharmaceuticals by 6.5% during the first quarter. Private Advisor Group LLC now owns 3,159 shares of the specialty pharmaceutical company’s stock worth $380,000 after purchasing an additional 192 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in shares of Jazz Pharmaceuticals by 17.1% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 2,418 shares of the specialty pharmaceutical company’s stock worth $291,000 after buying an additional 353 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Jazz Pharmaceuticals by 8.8% in the first quarter. Russell Investments Group Ltd. now owns 264,473 shares of the specialty pharmaceutical company’s stock valued at $31,848,000 after buying an additional 21,368 shares in the last quarter. ProShare Advisors LLC grew its position in Jazz Pharmaceuticals by 1.4% in the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock valued at $896,000 after acquiring an additional 105 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in Jazz Pharmaceuticals by 4.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 56,417 shares of the specialty pharmaceutical company’s stock valued at $6,794,000 after acquiring an additional 2,360 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.3 %

Shares of NASDAQ JAZZ traded up $0.33 during midday trading on Wednesday, reaching $128.07. The stock had a trading volume of 83,636 shares, compared to its average volume of 674,067. The company’s 50 day moving average price is $111.23 and its 200 day moving average price is $110.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The firm has a market cap of $7.74 billion, a price-to-earnings ratio of 17.99, a price-to-earnings-growth ratio of 1.16 and a beta of 0.57.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on JAZZ. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Piper Sandler cut their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Finally, Wells Fargo & Company reduced their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $175.00.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at $47,547,699.84. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.